Inactive Instrument

Highlights Trillium Therapeutics

Equities

TRIL

CA89620X5064

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Pfizer Deploying Some of Its Covid Cash in Arena Deal -- Analysis	21-12-13	DJ
Pfizer Eyes Enhanced Immuno-Inflammatory Disease Expertise With $6.7 Billion Arena Pharmaceuticals Takeover	21-12-13	MT
Pfizer Completes $2.22 Billion Trillium Therapeutics Acquisition	21-11-17	MT
Pfizer-Trillium Therapeutics $2.26 Billion Deal Secures Canada, US Approval	21-11-17	MT
Pfizer Inc. completed the acquisition of remaining 97.8% stake in Trillium Therapeutics Inc. from New Enterprise Associates 16, L.P., a fund managed by New Enterprise Associates, Inc., Avoro Capital Advisors LLC, RA Capital Healthcare Fund, L.P., a fund managed by RA Capital Management, L.P. and others.	21-11-16	CI
Trillium Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Trillium Therapeutics Brief: Says Received Final Court Order Approving Arrangement With PF Argentum ULC, a wholly-owned, indirect subsidiary of Pfizer Inc	21-10-28	MT
Trillium Therapeutics Brief: Securityholders Approve Acquisition by Pfizer	21-10-26	MT
DJ Industrial : Equities Rise After FDA Grants Full Approval to Pfizer, BioNTech COVID-19 Vaccine	21-08-23	MT
Pfizer : Strikes $2.26 Billion Deal to Purchase Trillium Therapeutics, Eyeing Enhanced Oncology Leadership	21-08-23	MT
Pfizer : To Buy Trillium Therapeutics	21-08-23	MT
Trillium Therapeutics : Pfizer to Acquire Trillium Not Already Owned For An Implied Equity Value of US$2.26 Billion	21-08-23	MT
Pfizer to Buy Remaining Shares of Trillium Therapeutics	21-08-23	DJ
Pfizer : to Acquire Trillium Therapeutics in $2.26 Billion Deal	21-08-23	MT
Trillium Therapeutics Brief: Statement Says This Represents a 118% Premium to 60-day Weighted Average Price for Trillium	21-08-23	MT
Trillium Therapeutics Brief: Pfizer to Acquire Trillium Not Already Owned For An Implied Equity Value of US$2.26 billion, or $18.50 per share, in cash	21-08-23	MT
Pfizer Inc. entered into a definitive agreement to acquire remaining 97.8% stake in Trillium Therapeutics Inc. from New Enterprise Associates 16, L.P., a fund managed by New Enterprise Associates, Inc., Avoro Capital Advisors LLC, RA Capital Healthcare Fund, L.P., a fund managed by RA Capital Management, L.P. and others for $1.9 billion.	21-08-22	CI
Trillium Therapeutics : Dual Listed Trillium Therapeutics Reports Q2 Net Loss of US$18.4 Million, Provides Update	21-08-13	MT
Trillium Therapeutics : Earnings Flash (TRIL.TO) TRILLIUM THERAPEUTICS Says Net Loss For Six Months Ended June 30, 2021 of US$29.3 Million Was Lower Than Loss of $39.5 Million a Year Earlier	21-08-13	MT
Trillium Therapeutics Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Trillium Therapeutics

Equities

TRIL

CA89620X5064

Highlights

Filters